Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Takeda Pharmaceutical Co Ltd    4502   JP3463000004

TAKEDA PHARMACEUTICAL CO LTD

(4502)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2020 3 344 B
EBIT 2020 -35 925 M
Net income 2020 -301 688 M
Debt 2020 4 455 B
Yield 2020 4,62%
Sales 2021 3 421 B
EBIT 2021 347 B
Net income 2021 149 B
Debt 2021 4 038 B
Yield 2021 4,62%
P/E ratio 2020 -50,5x
P/E ratio 2021 23,2x
EV / Sales2020 3,15x
EV / Sales2021 2,96x
Capitalization 6 070 B
More Financials
Company
Takeda Pharmaceutical Company specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. Net sales break down by activity as follows: - sale of drugs (95.5%); - sale of... 
Sector
Pharmaceuticals
Calendar
08/01Earnings Release
More about the company
Surperformance© ratings of Takeda Pharmaceutical Co L
Trading Rating : Investor Rating :
More Ratings
Latest news on TAKEDA PHARMACEUTICAL CO L
02:16aTAKEDA PHARMACEUTICAL : First iPSC-Derived CAR T-Cell Therapy Created by Kyoto U..
PU
07/09TAKEDA PHARMACEUTICAL : Continues Ongoing Inclusion in the FTSE4Good Developed I..
PU
07/09TAKEDA PHARMACEUTICAL : EIP Pharma Appoints Noel Donnelly as CFO
AQ
07/08TAKEDA PHARMACEUTICAL : Unveils New Data from the PROPEL Study at ISTH 2019, Rei..
AQ
07/08TAKEDA PHARMACEUTICAL : Ireland celebrates opening of new innovative manufacturi..
AQ
07/08TAKEDA PHARMACEUTICAL : Unveil New Data from the PROPEL Study at ISTH 2019, Rein..
BU
07/03TAKEDA PHARMACEUTICAL : Announces Baxalta's Successful Consent Solicitation with..
AQ
07/03ALEMBIC : Pharmaceuticals receives USFDA Approval for Febuxostat Tablets, 40 mg ..
AQ
07/03TAKEDA PHARMACEUTICAL : to Demonstrate Global Leadership in Hematology at ISTH 2..
BU
07/02TAKEDA PHARMACEUTICAL : Completes Sale of XIIDRA to Novartis
AQ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL CO L
More recommendations
Sector news : Pharmaceuticals - NEC
09:11aZYMEWORKS : Says Celgene Selects Lead Oncology Therapeutic Candidate Under Colla..
DJ
08:24aJOHNSON & JOHNSON : beats profit estimates on pharma strength, raises sales outl..
RE
08:23aJOHNSON & JOHNSON : beats profit estimates on pharma strength, raises sales outl..
RE
07:44aJOHNSON & JOHNSON : Bumps Up Sales Target--Update
DJ
07:39aJOHNSON & JOHNSON : Bumps Up Sales Target
DJ
More sector news : Pharmaceuticals - NEC
Chart TAKEDA PHARMACEUTICAL CO LTD
Duration : Period :
Takeda Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 5 395  JPY
Last Close Price 3 900  JPY
Spread / Highest target 61,5%
Spread / Average Target 38,3%
Spread / Lowest Target 15,4%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Costa Saroukos Chief Financial Officer
Andrew S. Plump Director, Chief Medical & Scientific Officer
Yasuhiko Yamanaka Managing Director & Head-Globalization
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL CO LTD7.73%56 852
JOHNSON & JOHNSON4.07%372 000
PFIZER-2.86%238 617
ROCHE HOLDING LTD.8.57%233 930
ROCHE HOLDING10.11%233 930
MERCK AND COMPANY5.95%208 546